Kuntz KM. Decision modeling for cost-utility analysis. Value Health. 2016;19:700–1. https://doi.org/10.1016/j.jval.2016.06.003.

Article  PubMed  Google Scholar 

Brazier J, Ara R, Azzabi I, Busschbach J, Chevrou-Séverac H, Crawford B, et al. Identification, review, and use of health state utilities in cost-effectiveness models: an ISPOR good practices for outcomes research task force report. Value Health. 2019. https://doi.org/10.1016/j.jval.2019.01.004.

Article  PubMed  Google Scholar 

Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96:5–21. https://doi.org/10.1093/bmb/ldq033.

Article  PubMed  Google Scholar 

Wolowacz SE, Briggs A, Belozeroff V, Clarke P, Doward L, Goeree R, et al. Estimating health-state utility for economic models in clinical studies: an ISPOR good research practices task force report. Value Health. 2016;19:704–19. https://doi.org/10.1016/j.jval.2016.06.001.

Article  PubMed  Google Scholar 

Papaioannou D, Brazier J, Paisley S. NICE DSU technical support document 9: The identification, review and synthesis of health state utility values from the literature [Internet]. National Institute for Health and Care Excellence (NICE), London; 2010. http://europepmc.org/abstract/MED/28481496

Zhou T, Chen Z, Li H, Xie F. Using published health utilities in cost-utility analyses: discrepancies and issues in cardiovascular disease. Med Decis Making. 2021;41:685–92. https://doi.org/10.1177/0272989X211004532.

Article  PubMed  PubMed Central  Google Scholar 

Nerich V, Saing S, Gamper E-M, Holzner B, Pivot X, Viney R, et al. Critical appraisal of health-state utility values used in breast cancer-related cost–utility analyses. Breast Cancer Res Treat. 2017;164:527–36. https://doi.org/10.1007/s10549-017-4283-8.

Article  PubMed  Google Scholar 

Bell CM, Chapman RH, Stone PW, Sandberg EA, Neumann PJ. An off-the-shelf help list: a comprehensive catalog of preference scores from published cost-utility analyses. Med Decis Making. 2001;21:288–94. https://doi.org/10.1177/0272989X0102100404.

Article  PubMed  CAS  Google Scholar 

Buchholz I, Janssen MF. EQ-5D-3L norms for the European older population: country-specific norms for 15 European countires based on the survey of health, ageing, and retirement in Europe. Value Health. 2023;26:721–32. https://doi.org/10.1016/j.jval.2022.09.2478.

Article  PubMed  Google Scholar 

Yang J, Jit M, Zheng Y, Feng L, Liu X, Wu JT, et al. The impact of influenza on the health related quality of life in China: an EQ-5D survey. BMC Infect Dis. 2017;17:686. https://doi.org/10.1186/s12879-017-2801-2.

Article  PubMed  PubMed Central  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ British Medical Journal Publishing Group. 2021;372:71. https://doi.org/10.1136/bmj.n71.

Article  Google Scholar 

Executive Board 146. Decade of healthy ageing: development of a proposal for a decade of healthy ageing 2020–2030: report by the Director-General [Internet]. World Health Organization, Geneva, 2020. https://iris.who.int/handle/10665/356347

Esposito S, Principi N, Rezza G, Bonanni P, Gavazzi G, Beyer I, et al. Vaccination of 50+ adults to promote healthy ageing in Europe: the way forward. Vaccine. 2018;36:5819–24. https://doi.org/10.1016/j.vaccine.2018.08.041.

Article  PubMed  Google Scholar 

Whang SD, Yim V, Cabrera M, Moore M, Lomazzi M. Implementing older adult vaccination within the Immunization Agenda 2030: a discussion of potential challenges and solutions. Popul Med. 2023;5:1–5. https://doi.org/10.18332/popmed/163244.

Article  Google Scholar 

Esme M, Topeli A, Yavuz BB, Akova M. Infections in the elderly critically-ill patients. Front Med. 2019. https://doi.org/10.3389/fmed.2019.00118.

Article  Google Scholar 

Tin Tin Htar M, Yerramalla MS, Moïsi JC, Swerdlow DL. The burden of respiratory syncytial virus in adults: a systematic review and meta-analysis. Epidemiol Infect. 2020;148:e48. https://doi.org/10.1017/S0950268820000400.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Aljunid SM, Mad Tahir NS, Ismail A, Abdul Aziz AF, Azzeri A, Zafirah SA, et al. Cost effectiveness of quadrivalent influenza vaccines in the elderly population of Malaysia. Sci Rep. 2023;13:18771. https://doi.org/10.1038/s41598-023-46079-y.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Allsup S, Gosney M, Haycox A, Regan M. Cost-benefit evaluation of routine influenza immunisation in people 65-74 years of age. Health Technol Assess. 2003;7:iii–x, 1–65. https://doi.org/10.3310/hta7240.

Article  PubMed  CAS  Google Scholar 

Altawalbeh SM, Wateska AR, Nowalk MP, Lin CJ, Harrison LH, Schaffner W, et al. Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older. Vaccine. 2024;42:3024–32. https://doi.org/10.1016/j.vaccine.2024.04.002.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Altawalbeh SM, Wateska AR, Nowalk MP, Lin CJ, Harrison LH, Schaffner W, et al. Pneumococcal vaccination strategies in 50-year-olds to decrease racial disparities: a US societal perspective cost-effectiveness analysis. Value Health. 2024;27:721–9. https://doi.org/10.1016/j.jval.2024.02.021.

Article  PubMed  PubMed Central  Google Scholar 

Alvarez FP, Allard L, Bianic F, Bricout H, Crépey P, Gaillat J, et al. Cost-effectiveness and public health impact of using high dose quadrivalent influenza vaccine in the French older adults population. J Med Econ. 2024;27:1300–7. https://doi.org/10.1080/13696998.2024.2404331.

Article  PubMed  CAS  Google Scholar 

Amiche A, Tanriover MD, Bellier L, Ugur B, Akin L. Cost utility of switching from trivalent to quadrivalent influenza vaccine in Turkey. Value Health Reg Issues. 2021;25:15–22. https://doi.org/10.1016/j.vhri.2020.11.006.

Article  PubMed  Google Scholar 

Atwood M, Beausoleil L, Breton M-C, Laferriere C, Sato R, Weycker D. Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults. Can J Public Health. 2018;109:756–68. https://doi.org/10.17269/s41997-018-0050-9.

Article  PubMed  PubMed Central  Google Scholar 

Averin A, Huebbe B, Atwood M, Bayer LJ, Lade C, von Eiff C, et al. Cost-effectiveness of bivalent respiratory syncytial virus prefusion F vaccine for prevention of respiratory syncytial virus among older adults in Germany. Expert Rev Vaccines. 2025;24:1–10. https://doi.org/10.1080/14760584.2024.2436183.

Article  PubMed  CAS  Google Scholar 

Baguelin M, Camacho A, Flasche S, Edmunds WJ. Extending the elderly- and risk-group programme of vaccination against seasonal influenza in England and Wales: a cost-effectiveness study. BMC Med. 2015;13:236. https://doi.org/10.1186/s12916-015-0452-y.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bartsch SM, O’Shea KJ, Wedlock PT, Ferguson MC, Siegmund SS, Lee BY. Potential clinical and economic value of Norovirus vaccination in the community setting. Am J Prev Med. 2021;60:360–8. https://doi.org/10.1016/j.amepre.2020.10.022.

Article  PubMed  PubMed Central  Google Scholar 

Bellier L, Petitjean A, Sarazu T, Tresierra J, Lopez JG. Cost-effectiveness analysis of switching from a trivalent to a quadrivalent inactivated influenza vaccine in the Peruvian immunisation programme. Vaccine. 2021;39:4144–52. https://doi.org/10.1016/j.vaccine.2021.05.084.

Article  PubMed  CAS  Google Scholar 

Bianculli PM, Bellier L, Mangado IO, Pérez CG, Mieres G, Lazarov L, et al. Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis. Hum Vaccin Immunother. 2022;18:2050653. https://doi.org/10.1080/21645515.2022.2050653.

Article  PubMed  PubMed Central  Google Scholar 

Blommaert A, Bilcke J, Willem L, Verhaegen J, Goossens H, Beutels P. The cost-effectiveness of pneumococcal vaccination in healthy adults over 50: an exploration of influential factors for Belgium. Vaccine. 2016;34:2106–12. https://doi.org/10.1016/j.vaccine.2016.03.003.

Article  PubMed  Google Scholar 

Boccalini S, Bechini A, Levi M, Tiscione E, Gasparini R, Bonanni P. Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy. Hum Vaccin Immunother. 2013;9:699–706. https://doi.org/10.4161/hv.23268.

Article  PubMed